Incyte
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT06416800
- Locations
- πΊπΈ
Fortrea Clinical Research Unit, Dallas, Texas, United States
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT06388564
- Locations
- π¬π§
Queen Elizabeth Hospital, Birmingham, United Kingdom
πΊπΈMayo Clinic Hospital, Phoenix, Arizona, United States
πΊπΈCity of Hope Medical Center, Duarte, California, United States
A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06380205
- Locations
- πΊπΈ
Celerion Clinical Research Unit, Tempe, Arizona, United States
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 144
- Registration Number
- NCT06313593
- Locations
- π³π΄
Oslo University Hospital, Oslo, Norway
πΊπΈStanford University, Palo Alto, California, United States
πΊπΈMoffitt Cancer Center, Tampa, Florida, United States
A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06310304
- Locations
- πΊπΈ
Celerion, Inc, Lincoln, Nebraska, United States
A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT06309394
- Locations
- π¬π§
Quotient Sciences Ltd, Nottingham, United Kingdom
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 958
- Registration Number
- NCT06259669
- Locations
- πΊπΈ
Syneos Health (remote site), Morrisville, North Carolina, United States
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Vehicle Cream
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 241
- Registration Number
- NCT06238817
- Locations
- πΊπΈ
Lynn Institute of the Ozarks, Little Rock, Arkansas, United States
πΊπΈFirst Oc Dermatology, Fountain Valley, California, United States
πΊπΈCenter For Dermatology Cosmetic and Laser Surgery, Fremont, California, United States
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 960
- Registration Number
- NCT06212999
- Locations
- πΊπΈ
Investigative Site US303, Phoenix, Arizona, United States
πΊπΈInvestigative Site US240, Scottsdale, Arizona, United States
πΊπΈInvestigative Site US307, Fort Smith, Arkansas, United States
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 23
- Registration Number
- NCT06213831
- Locations
- πΊπΈ
Saguaro Dermatology, Phoenix, Arizona, United States
πΊπΈAffiliated Dermatology, Scottsdale, Arizona, United States
πΊπΈFirst Oc Dermatology, Fountain Valley, California, United States